LifeMD Inc LFMD.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -19 cents. The mean expectation of seven analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -7 cents to 3 cents per share.
Revenue rose 22.8% to $62.22 million from a year ago; analysts expected $66.34 million.
LifeMD Inc's reported EPS for the quarter was a loss of 6 cents.
The company reported a quarterly loss of $2.85 million.
LifeMD Inc shares had fallen by 9.3% this quarter and gained 149.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 60% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for LifeMD Inc is $14.00, about 11.8% above its last closing price of $12.35
This summary was machine generated from LSEG data August 5 at 09:02 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)